Communiqués Xilio Therapeutics, Inc.

Actions

XLO

US98422T2096

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:30:00 09/09/2026			Varia. 5j.	Varia. 1 janv.
8,970 ^USD	+0,67%		+1,47%	+0,08%

12/08	Xilio Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
29/06	Xilio Therapeutics, Inc. annonce la nomination de Ben Harshbarger au poste de directeur juridique	CI

Communiqués

02/09	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
12/08	Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates	AQ
06/07	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
29/06	Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer	AQ
12/05	Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates	AQ
11/05	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 7, 2026	AQ
08/05	Xilio Therapeutics : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PU
07/05	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
17/04	Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2	AQ
16/04	Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors	AQ
03/04	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
23/03	Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results	AQ
17/03	Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting	AQ
12/03	Xilio Therapeutics Announces 1-for-14 Reverse Stock Split	GL
12/03	Xilio Therapeutics Announces 1-for-14 Reverse Stock Split	AQ
02/03	Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference	GL
02/03	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
12/02	Xilio Therapeutics Announces Pricing of Underwritten Offering	GL
08/01	Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates	GL
13/11	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results	GL
11/11	Xilio Therapeutics : Webcast Investor Call Vilastobart TMB Data (November 10, 2025)	PU
07/11	Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting	GL
07/11	Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting	GL
07/11	Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting	AQ
03/11	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL